Latest Elekta Stories
ATLANTA, June 11, 2014 /PRNewswire/ -- Elekta's MOSAIQ® Oncology Information System (OIS) has been tested and certified as a Complete Ambulatory EHR under the Drummond Group's Electronic Health
LONDON, June 5, 2014 /PRNewswire/ -- Elekta (NSE: EKTAb) and Royal Philips (NYSE: PHG, AEX: PHIA) announced today that The Institute of Cancer Research, London, a world-leading cancer research
Skyline Radiation Oncology, first in state to use Clarity, now also offers precise stereotactic radiotherapy for prostate cancer due to increased disease targeting confidence TUSTIN,
Largest medical center in the Netherlands upgrades with several Elekta Versa HD linear accelerators ROTTERDAM, the Netherlands, June 2, 2014 /PRNewswire/ -- Clinicians at the
Over 400 medical professionals from around the world attended the conference which featured over 100 presentations discussing the growing applications of SRS/SBRT in the treatment of tumors of
Multi-institutional radiotherapy planning study compared Leksell Gamma Knife Perfexion with three advanced linear-accelerator based stereotactic radiosurgery systems NEW YORK, May 21, 2014
Patients with five to 10 metastatic brain tumors who receive Gamma Knife radiosurgery live as long as those with two to four tumors post-therapy NEW YORK, May 13, 2014 /PRNewswire/
Progress reported in treatment of brain tumors, vascular malformations and functional disorders NEW YORK, May 8, 2014 /PRNewswire-USNewswire/ -- Over 500 participants from 40 countries,
Kettering Medical Center is first designated Center of Excellence KETTERING, Ohio, May 8, 2014 /PRNewswire/ -- Elekta has established a Center of Excellence program that seeks the
STOCKHOLM, May 8, 2014 /PRNewswire/ -- Elekta announced today that it has appointed Asa Hedin as Executive Vice President (EVP) Corporate Strategy, assuming responsibility for Strategy, Marketing
- a study of the individuals in a group of people within a specific context and their relationships.
- In rhetoric, the description of any one's personal appearance.